Fulton Bank N.A. Has $303,000 Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Fulton Bank N.A. decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 753 shares of the pharmaceutical company’s stock after selling 45 shares during the period. Fulton Bank N.A.’s holdings in Vertex Pharmaceuticals were worth $303,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Northwest Investment Counselors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth approximately $25,000. Dunhill Financial LLC increased its holdings in shares of Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares in the last quarter. Highline Wealth Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth approximately $27,000. GHP Investment Advisors Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth approximately $29,000. Finally, Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth approximately $33,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX opened at $409.56 on Friday. The company’s 50 day moving average price is $448.88 and its two-hundred day moving average price is $468.03. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The firm has a market cap of $105.47 billion, a PE ratio of -205.81 and a beta of 0.40. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the business posted $3.67 EPS. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Stifel Nicolaus increased their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a research note on Monday, December 16th. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. BMO Capital Markets decreased their price target on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research note on Friday, December 20th. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, December 20th. Finally, Barclays decreased their price target on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a research note on Friday, December 20th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $490.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.